COMPANY
Verastem Oncology
FDA-approved therapeutic company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Regulatory Affairs Associate | Boston, Massachusetts | Not stated | Oct 23, 2026 |
| Paralegal/Contract Manager | Boston, Massachusetts | Not stated | Oct 23, 2026 |
| Director/Senior Director, Trade and Distribution | Boston, Massachusetts | Not stated | Oct 15, 2026 |
| Senior Director, Clinical Scientist | Needham, Massachusetts | Not stated | Oct 11, 2026 |
| Medical Science Liaison/ Senior Medical Science Liaison (Boston) | Boston, Massachusetts, United States | Not stated | Oct 11, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 2 trial (NCT07659795, actual start Jul 28, 2026) (+1 other new trial); 3 clinical-operations roles open. ClinicalTrials.gov NCT07659795 (Jul 28, 2026)
Evidence (2 events)
- Jul 28, 2026 · ClinicalTrials.gov NCT07659795
leadSponsor.name='Verastem, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-28,type:ACTUAL}; studyFirstPostDate=2026-06-22; briefTitle='A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer' - Jul 22, 2026 · ClinicalTrials.gov NCT07659782
leadSponsor.name='Verastem, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-22,type:ACTUAL}; studyFirstPostDate=2026-06-22; briefTitle='A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer'
- Jul 28, 2026 · ClinicalTrials.gov NCT07659795
Timeline
- Trial start Phase 2: Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) source ↗
- Trial start 2: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer source ↗
- Trial start 2: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer source ↗
- Trial start 2: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer source ↗
- Trial start 1: A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors source ↗
- FDA FDA New drug/biologic (novel): AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) (avutometinib potassium; defactinib hydrochloride) — NDA219616, May 8, 2025. Applicant at approval: Verastem, Inc. Accelerated appr source ↗
- Trial start Phase 2: A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients source ↗
- Trial start Phase 3: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer source ↗
- Trial start Phase 1/Phase 2: Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer source ↗
- Trial start Phase 1/Phase 2: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients source ↗
- Trial start 1: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients source ↗
- Trial start Phase 1: Food Effect of VS-6766 in Healthy Adult Subjects source ↗
- Trial start Phase 2: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer source ↗
- Trial start Phase 2: A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation source ↗
- Trial start Phase 1: Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer source ↗
- Trial start Phase 1: Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects source ↗
- Trial start I: A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects source ↗
- Trial start 1: A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma source ↗
- Trial start Phase 2: Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants source ↗
- Trial start I: Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma source ↗
- Trial start I: Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies source ↗
- Trial start II: Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer source ↗
- Trial start Phase 2: Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma source ↗
- Trial start I: Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies source ↗
- Trial start I: Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer source ↗
Upcoming milestones
- 2027-06 (ESTIMATED) · 2 · A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer · NCT07644559
- 2027-06 (ESTIMATED) · 2 · A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer · NCT07659795
- 2027-06 (ESTIMATED) · 2 · A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer · NCT07659782
- Aug 1, 2027 (ESTIMATED) · Phase 2 · Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · NCT07747506
- Oct 15, 2028 (ESTIMATED) · Phase 3 · A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer · NCT06072781
- 2028-12 (ESTIMATED) · 1 · A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors · NCT07020221
Clinical trials (lead sponsor) 27
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | 2 | Recruiting | Jun 16, 2026 | 2027-06 (estimated) |
| NCT07659795 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | 2 | Recruiting | Jul 28, 2026 | 2027-06 (estimated) |
| NCT07659782 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | 2 | Recruiting | Jul 22, 2026 | 2027-06 (estimated) |
| NCT06072781 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Phase 3 | Recruiting | Mar 18, 2024 | Oct 15, 2028 (estimated) |
| NCT07747506 | Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | Phase 2 | Not yet recruiting | Aug 3, 2026 | Aug 1, 2027 (estimated) |
| NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | Phase 1/Phase 2 | Completed | Aug 1, 2022 | Jun 15, 2026 (actual) |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | 1 | Recruiting | Jun 24, 2025 | 2028-12 (estimated) |
| NCT05074810 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | 1 | Active, not recruiting | Apr 12, 2022 | 2026-06 (estimated) |
| NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients | Phase 2 | Active, not recruiting | Oct 30, 2024 | 2025-12 (estimated) |
| NCT05669482 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | Phase 1/Phase 2 | Active, not recruiting | Mar 22, 2023 | Aug 31, 2026 (estimated) |
| NCT04625270 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation | Phase 2 | Active, not recruiting | Dec 21, 2020 | Nov 15, 2024 (actual) |
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | Phase 2 | Terminated | Dec 12, 2013 | Jun 19, 2019 (actual) |
| NCT04620330 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer | Phase 2 | Completed | Dec 31, 2020 | Aug 29, 2023 (actual) |
| NCT05187169 | Food Effect of VS-6766 in Healthy Adult Subjects | Phase 1 | Completed | Dec 16, 2021 | Apr 12, 2022 (actual) |
| NCT02943317 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | Phase 1 | Terminated | 2016-10 | Aug 28, 2018 (actual) |
| NCT01849744 | Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies | I | Terminated | 2013-06 | 2017-04 (actual) |
| NCT02651727 | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects | Phase 1 | Terminated | 2015-09 | 2017-01 (actual) |
| NCT01778803 | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | I | Completed | Feb 26, 2013 | Feb 23, 2015 (actual) |
| NCT01951690 | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | II | Completed | 2013-09 | 2016-06 (actual) |
| NCT01943292 | Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies | I | Completed | Sep 2, 2013 | Jun 9, 2014 (actual) |
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma | Phase 2 | Terminated | 2013-09 | 2016-01 (actual) |
| NCT02913716 | A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects | I | Completed | 2015-08 | 2015-09 (actual) |
| NCT02372227 | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma | 1 | Terminated | 2015-01 | 2015-10 (actual) |
| NCT02215629 | Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | Phase 1 | Withdrawn | Not listed | 2016-09 (estimated) |
| NCT01991938 | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma | I | Terminated | 2013-11 | 2016-12 (actual) |
| NCT00787033 | A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies | Phase 1 | Completed | 2008-12 | 2011-03 (actual) |
| NCT00666926 | Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms | Phase 1 | Completed | 2005-12 | 2009-04 (actual) |
FDA records (last 2 years)
- FDA New drug/biologic (novel): AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) (avutometinib potassium; defactinib hydrochloride) — NDA219616, May 8, 2025. Applicant at approval: Verastem, Inc. Accelerated approval. source ↗
Open jobs 12
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Regulatory Affairs Associate | Boston, Massachusetts | Not stated | Oct 23, 2026 | Not stated |
| Paralegal/Contract Manager | Boston, Massachusetts | Not stated | Oct 23, 2026 | Not stated |
| Director/Senior Director, Trade and Distribution | Boston, Massachusetts | Not stated | Oct 15, 2026 | Senior |
| Senior Director, Clinical Scientist | Needham, Massachusetts | Not stated | Oct 11, 2026 | Senior |
| Medical Science Liaison/ Senior Medical Science Liaison (Boston) | Boston, Massachusetts, United States | Not stated | Oct 11, 2026 | Mid |
| Medical Science Liaison/Senior Medical Science Liaison (FL, AL, MS) | United States | Not stated | Oct 11, 2026 | Mid |
| Associate Director/Director Biostatistics | Needham, Massachusetts | Not stated | Oct 11, 2026 | Senior |
| Senior Director Biostatistics | Needham, Massachusetts | Not stated | Oct 11, 2026 | Senior |
| Senior Director, Translational Research | Needham, Massachusetts | Not stated | Oct 11, 2026 | Senior |
| Medical Director | Boston, Massachusetts | Not stated | Oct 11, 2026 | Senior |
| Vice President, Commercial Strategy and New Product Planning | Boston, Massachusetts | Not stated | Oct 11, 2026 | Executive |
| Senior Vice President Regulatory Affairs and Quality | Boston, Massachusetts | Not stated | Oct 11, 2026 | Executive |
Connect
See your connections at Verastem Oncology on LinkedIn (search by name, results not checked)